• Request support for nutrition coordination, information management and nutrition in emergencies

  • التماس الدعم لتنسيق التغذية وإدارة المعلومات والتغذية في حالات الطوارئ

  • Buscar apoyo para la coordinación de la nutrición, la gestión de la información y la nutrición en situaciones de emergencia

  • Demander un appui pour la coordination de la nutrition, la gestion de l'information et la nutrition dans les situations d'urgence

  • Solicite apoio para coordenação em nutrição, gestão de informação e nutrição em emergências

Publication: 17.05.2023

Nutritional care for Patients with Ebola Virus Disease in Ebola Treatment Units: Frequently Asked Questions

Photo Credit: © © UNICEF/UN0367791/Tremeau

A theme that has emerged consistently in interviews with professionals from past Ebola Virus Disease (EVD) outbreaks is the difficulty in knowing how to provide nutritional care in Ebola Treatment Units (ETUs); particularly, what type of nutritional care is feasible and how it can be balanced with the other clinical demands of a high-risk zone. The lack of research and evidence-based recommendations on the provision of nutritional care in ETUs has made it challenging to develop guidance on this topic. However, given the regular recurrence of EVD outbreaks, further practical guidance is needed to support health practitioners.

As a result of this gap, questions posed to the Global Nutrition Cluster Technical Alliance and based on previous work done on this topic, guidance on this topic was developed with technical input from a Taskforce established under the Alliance which was co-chaired by John Hopkins University/ CDC and the World Health Organisation.

This series of Frequently Asked Questions (FAQs) is meant to provide guidance on the provision of nutritional care in ETUs where recommendations are currently lacking or to aid the implementation of existing recommendations.  

These FAQs could be relevant to other infectious diseases with clinical syndromes similar to Ebola that are managed in isolation facilities, particularly diseases caused by other filovirus’ such as Marburg and Lassa.

These FAQs are ‘living’ documents and will be updated when new recommendations and/or evidence become available.

The FAQs are available here in English et ici en français​​​​​​​